Last reviewed · How we verify
RVT-501 0.5% ointment
RVT-501 0.5% ointment is a Small molecule drug developed by Dermavant Sciences GmbH. It is currently in Phase 2 development.
At a glance
| Generic name | RVT-501 0.5% ointment |
|---|---|
| Sponsor | Dermavant Sciences GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis (PHASE2)
- Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis (PHASE2)
- Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RVT-501 0.5% ointment CI brief — competitive landscape report
- RVT-501 0.5% ointment updates RSS · CI watch RSS
- Dermavant Sciences GmbH portfolio CI
Frequently asked questions about RVT-501 0.5% ointment
What is RVT-501 0.5% ointment?
RVT-501 0.5% ointment is a Small molecule drug developed by Dermavant Sciences GmbH.
Who makes RVT-501 0.5% ointment?
RVT-501 0.5% ointment is developed by Dermavant Sciences GmbH (see full Dermavant Sciences GmbH pipeline at /company/dermavant-sciences-gmbh).
What development phase is RVT-501 0.5% ointment in?
RVT-501 0.5% ointment is in Phase 2.
Related
- Manufacturer: Dermavant Sciences GmbH — full pipeline
- Compare: RVT-501 0.5% ointment vs similar drugs
- Pricing: RVT-501 0.5% ointment cost, discount & access